688317 之江生物
2024/03 - 三个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)0.702-3.41118.94128.67891.620
总资产报酬率 ROA (%)0.663-3.10416.89824.73173.925
投入资产回报率 ROIC (%)0.697-3.36818.63928.01955.708

边际利润分析
销售毛利率 (%)75.67365.12351.64562.48373.934
营业利润率 (%)61.305-54.49539.00544.63654.171
息税前利润/营业总收入 (%)-27.235-88.00234.12344.28155.329
净利润/营业总收入 (%)52.525-49.88732.68237.57345.416

收益指标分析
经营活动净收益/利润总额(%)108.354-7.35494.69398.460100.301
价值变动净收益/利润总额(%)0.0000.0000.0000.0000.000
营业外收支净额/利润总额(%)0.0794.555-0.652-0.530-0.222

偿债能力分析
流动比率 (X)16.22113.3837.4638.6874.107
速动比率 (X)14.95912.3116.5017.9543.765
资产负债率 (%)5.0856.11811.45610.04222.184
带息债务/全部投入资本 (%)0.3830.4991.1841.069--
股东权益/带息债务 (%)25,913.42719,878.5148,310.0489,211.1104,432.473
股东权益/负债合计 (%)1,866.6161,534.554772.931895.781350.766
利息保障倍数 (X)0.3072.847-7.370-370.35643.275

营运能力分析
应收账款周转天数 (天)176.733216.34134.28739.7190.000
存货周转天数 (天)1,800.1801,425.308128.576102.4730.000